Milestone Pharmaceuticals Stock Buy Hold or Sell Recommendation
| MIST Stock | USD 1.87 0.02 1.08% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Milestone Pharmaceuticals is 'Buy'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Milestone Pharmaceuticals given historical horizon and risk tolerance towards Milestone Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Milestone Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Milestone Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Milestone and provide practical buy, sell, or hold advice based on investors' constraints. Milestone Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Milestone |
Execute Milestone Pharmaceuticals Buy or Sell Advice
The Milestone recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Milestone Pharmaceuticals. Macroaxis does not own or have any residual interests in Milestone Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Milestone Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Good | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Milestone Pharmaceuticals Trading Alerts and Improvement Suggestions
| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (59.69 M) with profit before overhead, payroll, taxes, and interest of 5 M. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (46.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference |
Milestone Pharmaceuticals Returns Distribution Density
The distribution of Milestone Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Milestone Pharmaceuticals' future price movements. The chart of the probability distribution of Milestone Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Milestone Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Milestone Pharmaceuticals returns is essential to provide solid investment advice for Milestone Pharmaceuticals.
| Mean Return | 0.39 | Value At Risk | -2.11 | Potential Upside | 7.19 | Standard Deviation | 2.92 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Milestone Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Milestone Stock Institutional Investors
The Milestone Pharmaceuticals' institutional investors refer to entities that pool money to purchase Milestone Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Stonepine Capital Management Llc | 2024-06-30 | 1.2 M | Bml Capital Management Llc | 2024-09-30 | 1.1 M | Ikarian Capital, Llc | 2024-09-30 | 466 K | Altium Capital Management, Lp | 2024-09-30 | 440 K | Boxer Capital Llc | 2024-09-30 | 309 K | Envestnet Asset Management Inc | 2024-09-30 | 70.6 K | Ancora Advisors Llc | 2024-06-30 | 60 K | Squarepoint Ops Llc | 2024-06-30 | 54.7 K | Atria Investments Llc | 2024-09-30 | 40.4 K | Blackrock Inc | 2024-06-30 | 5 M | Rtw Investments, Llc | 2024-06-30 | 3.3 M |
Milestone Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 169K | 112K | (465K) | 730K | 839.5K | 881.5K | |
| Investments | (384K) | (70M) | 70M | (57.1M) | (25.9M) | (24.6M) | |
| Change In Cash | 33.9M | (47.5M) | 41.8M | (106.5M) | 6.1M | 6.4M | |
| Free Cash Flow | (51.6M) | (50.7M) | (33.2M) | (52.7M) | (46.5M) | (48.9M) | |
| Depreciation | 38K | 97K | 93K | 89K | 92K | 67.1K | |
| Capital Expenditures | 413K | 97K | 0.0 | 272K | 112K | 146.9K | |
| Net Income | (55.2M) | (50.0M) | (42.9M) | (58.4M) | (59.7M) | (62.7M) | |
| End Period Cash Flow | 119.8M | 72.3M | 114.1M | 7.6M | 13.8M | 13.1M | |
| Change To Netincome | 633K | 993K | 4.7M | 7.3M | 8.4M | 8.8M | |
| Other Non Cash Items | 1.6M | 5.5M | 7.3M | 44K | 2.4M | 2.5M |
Milestone Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Milestone Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Milestone Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Milestone stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.25 | |
β | Beta against Dow Jones | 1.11 | |
σ | Overall volatility | 2.92 | |
Ir | Information ratio | 0.09 |
Milestone Pharmaceuticals Volatility Alert
Milestone Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of 0.09 and Jensen Alpha of 0.25. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Milestone Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Milestone Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Milestone Pharmaceuticals Fundamentals Vs Peers
Comparing Milestone Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Milestone Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Milestone Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Milestone Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Milestone Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Milestone Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Milestone Pharmaceuticals to competition |
| Fundamentals | Milestone Pharmaceuticals | Peer Average |
| Return On Equity | -1.34 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Current Valuation | 76.26 M | 16.62 B |
| Shares Outstanding | 53.33 M | 571.82 M |
| Shares Owned By Insiders | 0.69 % | 10.09 % |
| Shares Owned By Institutions | 57.01 % | 39.21 % |
| Number Of Shares Shorted | 454.79 K | 4.71 M |
| Price To Earning | (4.44) X | 28.72 X |
| Price To Book | 4.11 X | 9.51 X |
| Price To Sales | 91.95 X | 11.42 X |
| Revenue | 1000 K | 9.43 B |
| Gross Profit | 5 M | 27.38 B |
| EBITDA | (56.84 M) | 3.9 B |
| Net Income | (59.69 M) | 570.98 M |
| Cash And Equivalents | 86.24 M | 2.7 B |
| Cash Per Share | 2.87 X | 5.01 X |
| Total Debt | 51.77 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 21.26 X | 2.16 X |
| Book Value Per Share | 0.39 X | 1.93 K |
| Cash Flow From Operations | (46.42 M) | 971.22 M |
| Short Ratio | 2.46 X | 4.00 X |
| Earnings Per Share | (0.80) X | 3.12 X |
| Target Price | 10.25 | |
| Number Of Employees | 47 | 18.84 K |
| Beta | 1.73 | -0.15 |
| Market Capitalization | 98.66 M | 19.03 B |
| Total Asset | 75.23 M | 29.47 B |
| Retained Earnings | (326.03 M) | 9.33 B |
| Working Capital | 65.81 M | 1.48 B |
| Current Asset | 110.42 M | 9.34 B |
| Current Liabilities | 7.17 M | 7.9 B |
| Net Asset | 75.23 M |
Note: Acquisition by Truex Paul F of 22870 shares of Milestone Pharmaceuticals at 1.54 subject to Rule 16b-3 [view details]
Milestone Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Milestone . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Milestone Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Milestone Pharmaceuticals? Buying financial instruments such as Milestone Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Milestone Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.